Edition:
United Kingdom

Brainstorm Cell Therapuetics Inc (BCLI.OQ)

BCLI.OQ on NASDAQ Stock Exchange Capital Market

3.16USD
16 Feb 2018
Change (% chg)

-- (--)
Prev Close
$3.16
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
16,058
52-wk High
$5.15
52-wk Low
$2.88

Chart for

About

Brainstorm Cell Therapeutics Inc. is a biotechnology company. The Company is engaged in developing adult stem cell therapies for debilitating neurodegenerative disorders, such as Amyotrophic Lateral Sclerosis (ALS, also known as Lou Gehrig's disease), Multiple Sclerosis (MS) and Parkinson's disease (PD), among others. Its... (more)

Overall

Beta: 1.54
Market Cap(Mil.): $75.75
Shares Outstanding(Mil.): 18.84
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 83.93 16.60
EPS (TTM): -- -- --
ROI: -- 1.66 10.66
ROE: -- 2.58 14.30

BRIEF-Brainstorm Cell Received Good Manufacturing Practice Approval From Israel Ministry Of Health

* BRAINSTORM CELL THERAPUETICS - RECEIVED GOOD MANUFACTURING PRACTICE APPROVAL FROM ISRAEL MINISTRY OF HEALTH FOR ISRAELI CONTRACT MANUFACTURING FACILITY

04 Jan 2018

BRIEF-Brainstorm Granted GMP Certification For Marketing-Level Manufacturing Of NurOwn

* BRAINSTORM GRANTED GMP CERTIFICATION FOR A MARKETING-LEVEL MANUFACTURING OF NUROWN® Source text for Eikon: Further company coverage:

03 Jan 2018

BRIEF-Brainstorm Cell Therapuetics names Eyal Rubin CFO

* Brainstorm strengthens executive team: appoints Eyal Rubin as chief financial officer

02 Nov 2017

BRIEF-Brainstorm reports Q3 loss per share of $0.13

* Q3 loss per share $0.13 Source text for Eikon: Further company coverage:

17 Oct 2017

BrainStorm enrolls first patients in advanced ALS stem cell trial

TEL AVIV BrainStorm Cell Therapeutics said the first patients have been enrolled in a late-stage trial of its treatment for amyotrophic lateral sclerosis (ALS) at Massachusetts General Hospital and UC Irvine Medical Center in California.

16 Oct 2017

BrainStorm enrolls first patients in advanced ALS stem cell trial

TEL AVIV, Oct 16 BrainStorm Cell Therapeutics said the first patients have been enrolled in a late-stage trial of its treatment for amyotrophic lateral sclerosis (ALS) at Massachusetts General Hospital and UC Irvine Medical Center in California.

16 Oct 2017

Earnings vs. Estimates